The role of gastro-esophageal reflux (GER) in systemic sclerosis and lung fibrosis

Angelo De Lauretis1,2
Alfredo Chetta1

1 Department of Respiratory Medicine, University of Parma, Parma, Italy
2 Interstitial Lung Disease Unit, Royal Brompton Hospital, London, UK

Address for correspondence:
Angelo De Lauretis, MD
Interstitial Lung Disease Unit
Royal Brompton Hospital
Sydney Street, SW3 6NP, London, UK
Phone: 020 7 351 8327 - Fax: 020 7 351 8336
E-mail: angelo.delauretis@gmail.com

Introduction
Systemic sclerosis (SSc) is an autoimmune condition characterized by tissue fibrosis of the skin and internal organs. Progressive interstitial lung disease (ILD) occurs in a significant subgroup of patients, and is now the main cause of death in SSc. Pathogenetic pathways believed to be involved in SSc-ILD are complex and include endothelial cell injury, inflammatory/immune activation and dysregulated fibroblast homeostasis (1). We have recently shown that a marker of epithelial cell permeability, such as inhaled technetium-99m-labelled diethylene triamine pentacetic acid (DTPA) clearance, is a strong predictor of lung function decline in SSc-ILD, even when lung disease severity is taken into account (2). Serum KL-6 (Krebs von den Lungen 6), a mucin-like glycoprotein expressed by type II pneumocytes (3), is also a marker of epithelial cell damage, upregulated in SSc-ILD and in other ILDs. In SSc-ILD, serum KL-6 is correlated with ILD presence, severity and activity (4-8). The finding of a tight link between epithelial cells markers and lung fibrosis suggests that damage to alveolar epithelial cells is likely to play a fundamental role, at least in a subset of patients. This highlights the need to focus on potential noxious factors for the respiratory epithelium as potential drivers of the progression of lung fibrosis.

Gastro-esophageal reflux (GER) has been suggested as a driving factor in the pathogenesis of both SSc-ILD and IPF (9, 10). The esophagus is affected in 50-82% of patients with SSc. Gastric reflux may be liquid, gaseous, or particulate; acid or nonacid; distal (localized to the distal oesophagus) or proximal (reaching the proximal oesophagus and pharynx). Reflux to the proximal oesophagus, which is intuitively linked to microaspiration into the lungs, appears to be quite common in patients with ILD-SSc and IPF. Importantly, a significant proportion of GER reflux is asymptomatic.

Concentration of pepsin and bile acids in bronchoalveolar lavage (BAL) and exhaled breath condensate (EBC) have been investigated as biomarkers of microaspiration in various respiratory diseases. The confirmation of a causative link of microaspiration in the genesis and progression of lung fibrosis would have a major impact in the management of ILD-SSc patients. It is likely that proteases such as pepsin, and not the acidity, are the primary target for future therapies. Potent inhibitors specific for proteases, e.g. pepstatin, are available and have been tested in phase-III clinical trials.

KEY WORDS: gastro-esophageal reflux, respiratory aspiration, microaspiration, pepsin, lung fibrosis, systemic sclerosis.
(13, 14). Importantly, a significant proportion of GER reflux is asymptomatic (15).

**The role of pepsin**
Repeated episodes of microaspiration of gastric contents secondary to GER could lead to alveolar epithelial injury and subsequent fibrosis. The histopathological characteristics of microaspiration-related changes have been poorly studied. Bronchiolecocentric organizing pneumonia, foreign bodies, intraluminal basophilic content have been described in surgical lung biopsies of ILD-SSc with possible microaspiration (16, 17). However, those histological features probably represent a small subgroup of ILD-SSc, while the vast majority of these patients show “pure” non specific interstitial pneumonia (NSIP) histopathologic pattern and GER is virtually present in all.

In addition to the well reported clinical association between GER in SSC and lung involvement (18-20), data from animal models and in vitro analysis have provided a biologic rationale supporting the role of microaspiration in the genesis and/or progression of ILD. Pepsin and bile acids have a citotoxic effect on epithelial cells and can induce a pro-inflammatory response including expression of cytokines and chemokines (21-23). In a rat model of chronic aspiration, interstitial pneumonitis changes followed the instillation into the airways of either whole gastric or neutralized gastric fluid, but not of hydrochloric acid (24). Indeed the fact that the refluxate loses its acidity when it approaches the proximal esophagus, may suggest that pepsin or other proteins found in the stomach content, instead of the acidity, are causative agents of lung fibrosis. Pepsin is inactive in an alkaline environment, but it remains stable and can reactivate when exposed again to acid (other reflux episodes) or taken up within epithelial cells by endocytosis (25). Notably, though virtually all SSC patients are on anti-reflux medications, henceforth no study have investigated the role of those medications on ILD-SSc.

**Gastro-esophageal reflux and ILD severity and progression**
The majority of studies performed in SSC so far have used indirect methods to assess microaspiration into the lungs and have not clearly discriminated between GER in SSC and lung involvement (35). Similarly, Savarino et al. reported that SSC patients with HRCT evidence of interstitial lung disease had a higher frequency of acid and non-acid reflux and a greater proportion of proximal reflux episodes, compared to those without ILD (14). However, it remains unclear whether GER is a risk factor for ILD progression. In the prospective study of 43 SSC patients by Marie et al., at two years from baseline, average fall in DLCO was 18% in those with severe esophageal dysfunction compared to 2% in the others (35). In a retrospective evaluation of 1043 SSC patient, GER symptoms and history of esophageal dilatation were predictive of ILD progression (20). By contrast, in another prospective study by Gilson et al., only a trend bordering on statistical significance was observed on univariate analysis between severe esophageal dysfunction and reduction in forced expiratory volume (FVC) at follow-up, which was not maintained after adjustment for disease severity, although only 7% of patients had extensive ILD involvement at baseline (FVC<70%) (36). Troshinsky et al. did not find a correlation between lung function and distal and/or proximal reflux in 39 consecutive SSC patients (37). In IPF, recent large retrospective analyses (38, 39) and a number of case series have suggested a link between GER.
suppression and better outcome (40, 41). The larger study that retrospectively analyzed 242 IPF patients assigned to receive placebo in previous randomized clinical trials, found a significant association between reported use of anti-acid medications and slower FVC deterioration (38). The Authors suggested that clinical trials testing the role of anti-GER therapies in IPF are warranted (38). Notably, though virtually all SSc patients are on anti-reflux medications, henceforth no study have investigated the role of those medications on ILD-SSc.

**Therapeutic implications and conclusions**

The confirmation of a causative link of microaspiration in the genesis and progression of lung fibrosis would have a major impact in the management of ILD-SSc patients. As discussed above, it is likely that proteases such as pepsin, and not the acidity, are the primary target for future therapies. Potent inhibitors specific for proteases, e.g. pepstatin, are available and have been tested in phase-III clinical trials (42). Anti-reflux surgery has a variable outcome in SSc; however a carefully selected subgroup of patients could be eligible for fundoplication if this could prevent lung fibrosis. It is clear that prospective studies to assess prevalence and characteristics of microaspiration among SSc patients with ILD are required. This information could be crucial in order to highlight patients at greater risk of disease progression and to plan for appropriately designed interventional studies on the effectiveness of anti-GER treatments.

**References**

The role of gastro-esophageal reflux (GER) in systemic sclerosis and lung fibrosis


